These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 29273395)
1. Hybrid peptide-small molecule oxytocin analogs are potent and selective agonists of the oxytocin receptor. Kablaoui N; Vanase-Frawley M; Sciabola S Bioorg Med Chem Lett; 2018 Feb; 28(3):415-419. PubMed ID: 29273395 [TBL] [Abstract][Full Text] [Related]
2. Design of Oxytocin Analogs. Wiśniewski K Methods Mol Biol; 2019; 2001():235-271. PubMed ID: 31134574 [TBL] [Abstract][Full Text] [Related]
3. Potent and selective oxytocin receptor agonists without disulfide bridges. Adachi Y; Sakimura K; Shimizu Y; Nakayama M; Terao Y; Yano T; Asami T Bioorg Med Chem Lett; 2017 Jun; 27(11):2331-2335. PubMed ID: 28438540 [TBL] [Abstract][Full Text] [Related]
4. Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs. Beard R; Stucki A; Schmitt M; Py G; Grundschober C; Gee AD; Tate EW Bioorg Med Chem; 2018 Jul; 26(11):3039-3045. PubMed ID: 29602673 [TBL] [Abstract][Full Text] [Related]
5. Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Ring RH; Schechter LE; Leonard SK; Dwyer JM; Platt BJ; Graf R; Grauer S; Pulicicchio C; Resnick L; Rahman Z; Sukoff Rizzo SJ; Luo B; Beyer CE; Logue SF; Marquis KL; Hughes ZA; Rosenzweig-Lipson S Neuropharmacology; 2010 Jan; 58(1):69-77. PubMed ID: 19615387 [TBL] [Abstract][Full Text] [Related]
6. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903 [TBL] [Abstract][Full Text] [Related]
7. Systematic N-methylation of oxytocin: Impact on pharmacology and intramolecular hydrogen bonding network. Sciabola S; Goetz GH; Bai G; Rogers BN; Gray DL; Duplantier A; Fonseca KR; Vanase-Frawley MA; Kablaoui NM Bioorg Med Chem; 2016 Aug; 24(16):3513-20. PubMed ID: 27297999 [TBL] [Abstract][Full Text] [Related]
8. Selective and potent agonists and antagonists for investigating the role of mouse oxytocin receptors. Busnelli M; Bulgheroni E; Manning M; Kleinau G; Chini B J Pharmacol Exp Ther; 2013 Aug; 346(2):318-27. PubMed ID: 23723434 [TBL] [Abstract][Full Text] [Related]
9. Selective and non-selective OT receptor agonists induce different locomotor behaviors in male rats via central OT receptors and peripheral V1a receptors. Wolfe M; Wisniewska H; Tariga H; Ibanez G; Collins JC; Wisniewski K; Qi S; Srinivasan K; Hargrove D; Lindstrom BF Neuropeptides; 2018 Aug; 70():64-75. PubMed ID: 29807652 [TBL] [Abstract][Full Text] [Related]
10. Agonist-specific, high-affinity binding epitopes are contributed by an arginine in the N-terminus of the human oxytocin receptor. Wesley VJ; Hawtin SR; Howard HC; Wheatley M Biochemistry; 2002 Apr; 41(16):5086-92. PubMed ID: 11955056 [TBL] [Abstract][Full Text] [Related]
12. Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor. Chan WY; Wo NC; Cheng LL; Manning M J Pharmacol Exp Ther; 1996 May; 277(2):999-1003. PubMed ID: 8627583 [TBL] [Abstract][Full Text] [Related]
13. Adolescent exposure to oxytocin, but not the selective oxytocin receptor agonist TGOT, increases social behavior and plasma oxytocin in adulthood. Suraev AS; Bowen MT; Ali SO; Hicks C; Ramos L; McGregor IS Horm Behav; 2014 May; 65(5):488-96. PubMed ID: 24631584 [TBL] [Abstract][Full Text] [Related]
14. Prosocial effects of an oxytocin metabolite, but not synthetic oxytocin receptor agonists, in a mouse model of autism. Moy SS; Teng BL; Nikolova VD; Riddick NV; Simpson CD; Van Deusen A; Janzen WP; Sassano MF; Pedersen CA; Jarstfer MB Neuropharmacology; 2019 Jan; 144():301-311. PubMed ID: 30399367 [TBL] [Abstract][Full Text] [Related]
15. Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. Jorgensen WT; Gulliver DW; Werry EL; Reekie T; Connor M; Kassiou M Eur J Med Chem; 2016 Jan; 108():730-740. PubMed ID: 26741855 [TBL] [Abstract][Full Text] [Related]
16. Molecular basis for agonist selectivity in the vasopressin/oxytocin receptor family. Chini B; Mouillac B; Ala Y; Balestre MN; Cotte N; Trumpp-Kallmeyer S; Hoflack J; Elands J; Hibert M; Manning M Adv Exp Med Biol; 1995; 395():321-8. PubMed ID: 8713982 [TBL] [Abstract][Full Text] [Related]
17. Investigation of pyrazolo-sulfonamides as putative small molecule oxytocin receptor agonists. Katte TA; Reekie TA; Werry EL; Jorgensen WT; Boyd R; Wong ECN; Gulliver DW; Connor M; Kassiou M Eur J Med Chem; 2017 Aug; 136():330-333. PubMed ID: 28505537 [TBL] [Abstract][Full Text] [Related]
19. Design of oxytocin antagonists, which are more selective than atosiban. Manning M; Stoev S; Cheng LL; Wo NC; Chan WY J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184 [TBL] [Abstract][Full Text] [Related]
20. Oxytocin synthesis and oxytocin receptor expression by cell lines of human small cell carcinoma of the lung stimulate tumor growth through autocrine/paracrine signaling. Péqueux C; Breton C; Hendrick JC; Hagelstein MT; Martens H; Winkler R; Geenen V; Legros JJ Cancer Res; 2002 Aug; 62(16):4623-9. PubMed ID: 12183418 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]